transplants because of staffing crises. I now hear rumours from hospital managers in West Yorkshire that our EU recruiting drive has been sabotaged by the referendum result and we will not get the staff we recruited because of very reasonable fears for the future. British patients will lose out."
Chris Hopson, chief executive of NHS Providers, said that it was important to reassure workers from other EU countries about job security. "This is vital to ensuring that EU nationals considering coming to work as health and care professionals in the UK are not deterred from doing so. Anecdotal indications are that this is already happening," he warned.
The Royal College of Radiologists said it had already been contacted by clinical radiologists and oncologists from other EU states working in the UK and concerned about their employment status after the referendum result. A consultant doctor from Poland working in the north of England, who wished to remain anonymous, said that he would advise Polish doctors to "think again" about coming to work in the UK because of the uncertainty Brexit had created. Gareth Iacobucci, The BMJ
Abolish locum cap
Delegates called for abolition of the cap on hospital doctors' locum rates. Proposing the motion, Thomas Micklewright, a junior doctor, said, "'Locuming' is an active career choice for many, including working parents and foreign doctors. These caps are a death knell for working outside of a training contract."
Decriminalise abortion
Doctors asked the BMA to work towards decriminalising abortion. After the vote was agreed John Chisholm, chair of the BMA medical ethics committee, said, "Despite the BMA's longstanding role in the abortion debate, the BMA does not have a clear view on decriminalisation." He said that the medical ethics committee would produce a briefing paper on the current law and would look at what decriminalisation actually means.
Drug regulation
Astellas UK is suspended from ABPI after "deception"
The UK subsidiary of the Japanese drug company Astellas had its membership of the Association of the British Pharmaceutical Industry suspended for 12 months over "deception on a grand scale."
The decision related to a complaint about an advisory board meeting held in Milan, Italy, in February 2014 at which Astellas promoted the benefits of its prostate cancer medicine, Xtandi (enzalutamide), for what was an unlicensed indication at the time. Astellas then knowingly provided incorrect information about the event to an investigation. (Full story doi:10.1136/ bmj.i3574)
Brexit

Hunt may run for PM
As The BMJ went to press, the health secretary for England, Jeremy Hunt, announced that he was "seriously considering" running for the Conservative Party leadership. He told ITV's Good Morning Britain on Tuesday, "I want to start making an argument as to what we do next as a country" after the EU referendum. Hunt has already called for a second referendum on the terms of Britain's EU exit. The £100m a year childhood flu vaccination campaign in the UK will continue despite evidence from the US that the inhaled vaccine is ineffective. Public Health England (PHE) said that its data contradict those of the US Advisory Committee on Immunization Practices, which recently advised the Centers for Disease Control and Prevention (CDC) to stop vaccinating children because, for the past three flu seasons, the vaccine seemed to have little effect.
Diane Abbott is new shadow health secretary
PHE published provisional figures for the UK which showed that the inhaled vaccine taken by 2 to 17 year olds achieved similar protection against laboratory confirmed flu as did adult vaccines in older age groups. The vaccine prevented flu in more than half of the children given it, with an effectiveness of 57.6% (95% confidence interval 25.1% to 76%). Similar results had been reported by the Finnish National Institute for Health and Welfare, which found an effectiveness of 46%.
Richard Pebody, head of flu surveillance for PHE, said, "We remain confident that the vaccines used in the annual flu vaccine programme are the most effective that are currently available in protecting both those vaccinated and in reducing transmission of the flu virus in our communities."
By contrast, data collected by the US Influenza Vaccine Effectiveness Network for the 2015-16 season showed only 3% effectiveness in 2 to 17 year olds (-49% to 37%) with the inhaled vaccine, compared with 63% (52% to 72%) with the injected vaccine.
Scientists have been puzzled at the apparent ineffectiveness of FluMist [Fluenz in the UK], which is contested by AstraZeneca. The company stated that it would continue to work with the CDC "to better understand its data to help ensure eligible patients continue to receive the vaccine in future seasons."
Public health
Children call for obesity action
Children favour a ban on takeaways delivering food to school gates and want to see initiatives such as loyalty cards that reward healthy food choices, a report published by the Royal Society for Public Health showed. The Child's Obesity Strategy found that a quarter of young people aged 13 to 17 had ordered a takeaway to their school, that half blamed fast food manufacturers for rising child obesity, and that 82% thought food manufacturers misled consumers through food labelling. "It was always a ridiculous claim to make, the idea there was £350m a week," she told The BMJ. "Not only was it on the side of the bus but it was also alongside the NHS logo, which they deliberately used because it's a very trusted brand. They should never have been allowed to make that claim."
Air pollution causes excess deaths in France
What the NHS needs is a strong economy and that requires "stability and confidence," she added.
But all those who before the referendum predicted an economic downturn are continuing to issue dire warnings. The morning after the referendum result the Economist Intelligence Unit mapped out "high disruption" and "low disruption" scenarios for the UK economy and politics. (The low disruption scenario saw David Cameron and Boris Johnson working together to restore stability.) The high disruption scenario, which the report says is more likely, sees gross domestic product 6% lower in 2020 than if the UK had remained in the EU. Most economic forecasters predict lower economic growth reducing tax revenues and hence reducing the opportunity to spend more on the NHS.
How will Brexit affect the pharmaceutical sector?
The European Medicines Agency is based in London, which gives the UK regulatory clout. Most predict that the agency will have to move from its London headquarters.
A low disruption scenario sees David Cameron and Boris Johnson working together
BEYOND THE REFERENDUM
KIERAN WALSHE, Manchester Business School
The NHS and universities both have highly internationalised and mobile workforces, and both benefit from the free movement of people within Europe. If Brexit threatens that free movement, or makes the UK a less attractive place to live and work, it will have a profound effect on health services and on higher education and research.
The best and the brightest, and those earlier in their careers with fewer institutional or family ties, are likely to vote with their feet and leave. NHS staff shortages and a downturn for research and higher education will follow.
NICKY CULLUM, head of the school of nursing, midwifery, and social work,
University of Manchester
The NHS does not have enough nurses and midwives. Most trusts have been actively recruiting nurses from as far afield as India and the Philippines. Any change that makes the UK seem less welcoming for European health workers will be another shot in the foot. A positive effect of Brexit will be that we will no longer have to adhere to EU requirements for nurse training which say that prequalifying courses must comprise 4600 hours of study, at least 2300 of which has to be in clinical placements. Excellent clinical competency can be gained in far less time.
SIMON WESSELY, president of the Royal College of Psychiatrists
There will be less money for the NHS and science. I cannot hide my anger with how swiftly the something that those arguing to leave the EU wanted to lessen.
Ismail believes that the two year negotiation will not be enough time to go through all the legislation affecting health such as energy, tobacco products, food standards, and environmental protection.
"We would have to go through about 80 000 pages of regulation and decide whether we want to keep, repeal, or amend them," he says.
Anne Gulland, freelance journalist, London, UK
Cite this as: BMJ 2016;353:i3595
The Unified Patent Court, to which the UK is a signatory and which will grant patents with legal jurisdiction across the EU, is also due to open offices in London in 2017. Its future is now uncertain, as is the UK's involvement in the court.
EU clinical trials regulations are also expected to take effect in 2017-18, harmonising procedures for the assessment of applications for clinical trials and increasing transparency in trial outcomes. Whether the UK will still enact the regulations and the effect of being outside the regulations are unclear.
Another area where there is a big question mark is around access to EU research funding, including Horizon 2020. Will researchers who currently have grants be able to keep them? And what access will they get after 2020? The UK gets around 15% of the fund currently, but non-EU countries such as Israel and Norway also have access. However, they have to pay into the scheme and cannot influence research policy.
Clifford Holt, a senior editor at Pan European Networks, a company that monitors the Horizon 2020 grants, says that organisations currently in receipt of funding will continue to have access because grants have already been assigned.
"But future funding is in question," he says.
Another concern is drug sales. In its report on the effects of Brexit on the economy the Economist Intelligence Unit predicts that pharmaceutical sales will total £19bn by 2020, compared with £21bn if the UK were to remain in the EU.
What key public health legislation will be affected? Nasrul Ismail, visiting research fellow and public health law expert at Bristol University, says that the public health legislation most likely to be repealed in a post-Brexit UK are the regulations governing air and water quality. The second reason [that I voted to leave] was the public procurement act which stopped a clinical commissioning group trying to reorganise services in a particular way-they were told that they would have to put it out to tender because of EU law. The NHS runs very differently in the UK from other places in Europe and we need solutions that are specific to the UK.
MICHAEL MARMOT, director of UCL Institute of Health Equity
Around 90% of economists predicted that, in the case of Brexit, we would be a poorer country in the short and medium term. A poorer country will have less money to spend on social services, healthcare, education, and research: this will damage health. We recruit foreign nurses and doctors because we don't train enough of our own. If it becomes more difficult to recruit, we will have to find the money to train more or do without, with adverse consequences. Just as important as all this, for me, is the message that Brexit sends. What I do in my day job is promote learning from other countries and cultures, sharing of perspectives, realising that we have common purposes in improving people's lives, and creating health equity. The Brexit campaign promoted an image of a Britain that stands apart, unwilling to cooperate with other nations in dealing with the challenges we all face: global inequality, climate change, tax avoidance, human rights.
What does Brexit mean for doctors working in the UK?
Extricating the UK from the EU will have an impact on the UK's medical workforce. Tom Moberly reports Doctors from other European Union countries make a huge contribution to the NHS. One in 10 doctors registered in the UK qualified in another EU country (see figure, right), and over a quarter of doctors entering the medical register each year are from other EU countries.
Sarah Wollaston, the Conservative MP and chair of the parliamentary health select committee, said that the effect on the workforce was the most worrying aspect of Brexit. "We have 130 000 people working in the NHS who qualified elsewhere in the EU," she told The BMJ. "The number one priority is to make sure they still feel welcome and those who are in the process of being recruited are given a reassuring message. They have to feel that coming to Great Britain is a positive step. No one is suggesting that people who are already here are going to have to leave-we have to give out a reassuring message." Samantha Currie, senior lecturer at the University of Liverpool's School of Law and Social Justice, believes that the process of deciding the status of EU immigrants in the UK, as well as UK nationals living in other EU countries, will "constitute a significant part" of the Brexit negotiation process. "It will take time for clarity to emerge and, in the meantime, EU migrant workers in the UK will undoubtedly experience a greater sense of uncertainty than they have been used to as a consequence of the referendum result."
Working Time Directive
One EU initiative that has long been the focus of opposition from the government and parts of the medical profession is the European Working Time Directive. "It is clear that the Working Time Directive has been a particularly contentious measure in the UK," Currie says. "From this point of view, any continuation of the working time rules is likely to face some opposition."
Jason Heyes, professor of employment relations and director of the Work, Organisation and Employment Relations Research Centre, says that another piece of employment legislation that a future government might want to look at is the agency worker regulations. "These give agency workers who've been working in the same job for 12 weeks the right to the same basic employment and working conditions as comparable employees," he says. "In the health service that applies to many locums, and some people are very unhappy about that."
But Heyes points out that these changes will take time. "Nothing is going to happen immediately as far as employment law is concerned," he says.
Currie says that "it is impossible to present a clear long term picture" of how the rights of EU migrant healthcare professionals working in the UK may change. "For now, however, it is important to remember that from a legal point of view nothing has yet changed," she said. "EU migrants' residency, employment, and social security rights remain intact for the time being," she explained. There are also valid tax reasons for leaving-for example, if a large tower block is built in Canary Wharf, the company won't pay any capital gains tax or corporation tax in the UK. This is because EU treaties let it pay tax in Denmark where the rates are almost zero. George Osborne can alter the tax rate as much he wants, he won't collect a penny. As a nation we are unable to subsidise the steel industry in Wales because we are banned by EU regulation. Consequently thousands will lose their jobs at the hands of EU bureaucrats.
MIKE DIXON, GP and chair of NHS Alliance
I fear that [the vote] may have a negative impact on research and development and that there will be a negative impact on the pharmaceutical industry. On the plus side, we will no longer be bound by the European Working Time Directive or by European competition rules. There might also be an opportunity to overcome the legal red tape around litigation that leads to a yearly bill of £1bn for the NHS, and where redress should have different rules in a health service that is free at the point of delivery. The NHS is stronger than any one government or vote. Current instability might encourage some radical thinking such as dropping Payment by Results and properly supporting family medicine.
SARAH MAIN, director of the Campaign for Science and Engineering
This outcome provides a real challenge for our sector. Science is an area where the relationship between the UK and the EU was particularly beneficial. 
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Brexit threatens stability of medical research workforce
The UK's exit from the EU will threaten the stability of the medical science workforce by undermining projects funded by the EU and could make the UK a less attractive place for EU scientists to work, researchers have warned.
Rustam Al-Shahi Salman, a professor of clinical neurology at the University of Edinburgh, told the online publication Vox, "Brexit will immediately destabilize our ongoing European Union-funded multi-center studies." He said that the future of projects being established or seeking funding would now be less certain, because such projects were all planned under EU regulation.
Funding
The UK relies heavily on the EU to staff and fund its research efforts. About 23% of research scientists are from other EU countries, and about 5% of students in the UK are from other EU countries. In addition, about 10% of funding for research in UK universities comes from the EU. The UK receives 16% of research funding from the EU, equating to more than £8bn between 2006 and 2015.
Collaboration
Venki Ramakrishnan, president of the Royal Society, said that EU funding "has been an essential supplement to UK research funds." He added, "One of the great strengths of UK research has always been its international nature, and we need to continue to welcome researchers and students from abroad. Any failure to maintain the free exchange of people and ideas between the UK and the international community, including Europe, could seriously harm UK science." It is thanks to evidence based medicine, however, that we have learnt about the corruption of the evidence and about the flawed production and dissemination of guidelines. From the beginning, a core clinical principle of evidence based medicine stated that the evidence alone should never dictate care for a patient. The authors are right to critique guidelines when they fail to account for the shortcomings of evidence or forget the core clinical principle and fail to contribute to the work of caring for people. And when guidelines do fail, new or adapted evidence based medicine tools should emerge to ensure individualised care for each patient. In advancing these JIM VARNEY/SPL Ian Hargraves, designer, Marleen Kunneman, postdoctoral research fellow, Juan P Brito, assistant professor of medicine, Victor M Montori, professor of medicine, Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, USA montori.victor@mayo.edu
EDITORIAL
Caring with evidence based medicine
Evidence alone should never dictate care for a patient when guidelines make strong recommendations-we breed hubris, a sense that medicine is simply a matter of knowing what to do and that all the best clinicians and their patients should have this ability at their fingertips. Anyone who lives with or cares for people with depression, cancer, or heart disease knows that this is rarely the case. The real challenge is to deal with illness and how it fragments, disarticulates, and renders uncertain the conduct and dignity of human lives.
Maintaining a critical eye on the contribution of evidenced based tools to the care of individual patients is the way forward. Guidelines serve well to communicate our understanding of what's best for most patients when this is clear. In less clear situations, appropriately constructed guidelines are also helpful, as some guidance is often better than none.
Shared decision making should not be seen as the communication of expert knowledge or preference, or as the joint review of knowledge summaries designed for the consultation.
In our work, we emphasise shared decision making in conversations.
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The conversation is an appropriate environment to use evidence from clinical research to help distinguish among available options-a set of options perhaps curated in guidelines.
8 Options are hypotheses for what is best for this patient now. These hypotheses are tested in conversation until a purposeful path forward becomes clear. It is in conversation that clinicians and patients draw out the importance of evidence, options, biography, purpose, goals, and needs as these contribute to an individualised treatment plan. In so doing, evidence based medicine, as originally intended, becomes careful and kind care. new tools, however, we must be careful not to fetishise them.
No simple answer
Analysing video recordings from our experience in developing and testing aids for use in clinical encounters has been sobering. We have seen sophisticated forms of persuasion in which the decision aid is used as a prop. We have seen encounters in which the technical steps for shared decision making are as evident as the lack of real connection with the patient. Like guidelines, shared decision making and the aids that support it don't necessarily result in care.
Both guidelines and shared decision making fail when they seek to inject certainty rather than do justice to the uncertainty of illness. When we seek certainty in the tools we risk making evidence, clinical practice, and the articulation of patient preferences definitive rather than contributory in caring for the person. By unduly advancing certainty-for instance, 
Weak link
Two stories are a slim sample on which to base conclusions, but that is all the authors cited, after describing "widespread media coverage" over a six month period that was both "intense" and "negative." In one story, less than 20% of the text discusses potential harms.
2 The headline of the other story was "Doctors' fears over statins may cost lives, says top medical researcher." We should not rush to judge the media's role in this episode. The authors provide no patient survey data to support the belief that people stopped because of news reports.
It 
Reasons unknown
What do we know about patients' preferences in this case? Perhaps news stories inspired patients to question trade-offs in ways they never did when they started taking statins because they had not been fully informed. We know nothing about the quality of the clinical decision making encounters before the start of treatment. We know nothing about why these patients stopped. A survey in the United States found that patients perceive that physicians tend to emphasise the advantages more than the disadvantages in 10 common decisions about care.
6 Furthermore, patients in that survey reported that treatment of raised cholesterol concentration was one of the decisions for which they were least likely to be asked for input.
So We rarely see journalism about overdiagnosis, overtreatment, or shared decision making. Few stories clearly communicate the trade-offs involved in medical decisions. Far more stories fawningly promote more use of more interventions, evidence be damned. Journalism that exposes the public to ongoing controversies in science should be nurtured, not branded as negative.
Matthews and colleagues projected excess cardiovascular events as a result of discontinued statin use.
1 They did not explore the possibility of reduced reports of muscle pain, rhabdomyolysis, liver damage, diabetes, or cognitive side effects.
If news stories generate new questions from patients, or more complete conversations between patients and clinicians including better discussions on trade-offs, personal preferences, and values, that is an outcome to embrace. In the end, I suggest that this episode is far less about journalism than about how science and medicine deal with uncertainty. John R King asks, "How valid is a difference of 48% to 52% in the referendum result? Given the fluctuation of sentiment from day to day, the vagaries of the weather, not to mention that some early postal voters have now woken up to the reality of what Brexit means and changed their minds, to base an epic decision on such a slender majority on a particular day seems ridiculous. For assisted suicide, a clear and settled intention is an essential requirement. Brexit should have specified a similar condition." Michael H Stone says, "I found it stomach-churning that many politicians who I feel sure would never have voted to establish an essentially free at the point of use, and paid for out of general taxation, NHS, and who I think given the chance would either destroy or 'privatise' the NHS, 'stood behind' this 'we would have another £350m a week to spend on the NHS if we left the EU'." Goh Shyan writes, "Some readers who claim that healthcare professionals should treat non-residents essentially the same as UK residents, are simply careless about the basic principles of financial budgeting in the NHS; when there is a limit in the spending budget, there is also a limit to how many people you can provide a service to within a timeframe. The inclusion of illegal migrants or non-residents on the NHS waiting list no doubt means a delay of services to some UK residents (for which the NHS is funded) regardless of whatever ethical arguments people use. This fact polarises opinion of UK migration within those groups of people with lower socioeconomic status or reduced access to higher education, income, or employment."
Did you vote leave, and do you think that this will have a positive effect on healthcare in the UK? The two are not, of course, unconnected. In fact, the measure of problems of getting out of hospital-delayed transfers of care-connects with the whole process of hospital and out-ofhospital care, from the use of beds and clinical decisions to treat, to the flows (and blockages) in emergency departments. Apart from the costs of delays to patients in emotional and health terms, the cost to the NHS has been estimated at £900m a year.
2 Other estimates put it at around £540m a year.
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The numbers of patients in a hospital bed but ready to be discharged fell between 2007 and 2010, and then stayed relatively steady from 2010 to about 2013. However, in the past two to three years the number of patients delayed has risen by about 50% (fig 1) -far outstripping the increase in patients being admitted to hospital. The latest figures for England show that in April this year nearly 6000 patients who were ready to leave could not be discharged-accounting for around 168 000 patient days-compared with about 4000 in 2013-14.
Although the problem is perhaps popularly supposed to be securing out-of-hospital support from social care for patients ready to go home or into residential or nursing homes, around 60% of patients are currently delayed in hospital because of problems attributable to the NHS, such as waiting for assessments or delays in arranging a move to other NHS facilities (fig 2) . No of delayed patients in hospital beds/month R 2 = 0.4989
Nevertheless, while delays attributable to social care are in the minority-around 33% of all delayed patients-over the past three years they have grown by 92% compared with a 19% increase in delays attributable to the NHS. 4 The effects of funding cuts for local authorities plus increasing difficulties in the care home market are likely to have contributed to this trend.
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Delayed discharge
Delays in discharging patients have knock-on effects and will have contributed to increasing bed occupancy rates. These, on average across all hospitals in England, have risen from around 85% to 89% over the past eight years (fig 3) . This apparently small increase in the national average obscures the fact that the number of hospitals with over 90% average occupancy across the year increased from 49% to 74% between 2007-08 and 2015-16. 6 Increasing numbers of delayed discharges also backs up into other parts of hospitals. For example, the problem with increasing numbers of emergency department patients having to wait more than the government's target of four hours to admission, transfer, or discharge is strongly linked not to the front door (increasing attendances) but to the back door, with problems in admitting patients to other parts of the hospital. And, in turn, there is an observed positive association between the numbers of emergency department patients waiting more than four hours to be either admitted into hospital, transferred out of the department, or discharged home and the number of patients waiting to vacate a bed elsewhere in the hospital (fig 4) . 7 As a recent report on delayed transfers of care has noted, there's no silver bullet that will improve the situation. 5 Local authorities have been subject to fines since 2004 for delays that can be attributable to services for which they are responsible.
8 While this may have had some effect in its early years, recent increases in delays arising from social care perhaps suggest such financial disincentives have lost their bite. As the varied reasons for delays suggests (fig 2) , solutions too are varied-from better funding of demand for health and social care at a national level, through to better discharge planning and perhaps a review of the financial (dis)incentives faced by the NHS and local authorities. The cost of delays to the NHS has been estimated at £900m a year. Other estimates put it at around £540m
